Although many antidepressants with multiple mechanisms of action are available, there is an unmet need to create effective medications in patients who do not respond to commercially available treatments. The most commonly used antidepressants for treating major depressive disorder (MDD) involve serotonin (5-HT) and norepinephrine (NA), but there is also reason to believe that dopaminergic (DA) mechanisms may have a role in antidepressant response.

GSK372475 is a triple reuptake inhibitor with approximately equipotent inhibition of 5-HT, NA and DA transporters. Two studies evaluated the efficacy, safety and tolerability of GSK372475 in outpatients (aged 18-64 years) with a major depressive episode associated with MDD. The two 10-week, randomized, double-blind, parallel-group, placebo and active-controlled studies were followed by a 1- to 2-week tapering phase and a 5- to 8-week follow-up. Patients were randomized in a 1:1:1 ratio in both studies to receive either GSK372475 (1.5-2 mg/d) in study 1 or GSK372475 (1-1.5 mg/d) in study 2, venlafaxine XR (150-225 mg/d) in study 1 or paroxetine (20-30 mg/d) in study 2, or placebo.

In both studies, there was no significant difference between the GSK372475 and placebo groups on any of the primary efficacy endpoints (six-item Bech scale, IDS-Clinician Rated, MADRS). Both active controls showed significant improvement on all clinical efficacy measures compared to placebo. Dry mouth, headache, insomnia and nausea were the most common adverse events (AEs) with GSK372475. Compared with placebo, GSK372475 resulted in a higher percentage of AEs related to sleep, anxiety, gastrointestinal, and cardiovascular (tachycardia) in both studies.

Increases from baseline in sitting blood pressure (systolic and diastolic) and heart rate measurements were observed with GSK372475 compared with active controls and placebo. Dropout rates were higher for GSK372475 than for placebo, venlafaxine XR, or paroxetine. These results do not support the idea that triple reuptake inhibition is a useful antidepressant mechanism.

About the Author



2004- MS, psychology- Walden University, Minneapolis, MN